2021 - 2024 Novel Liver Cirrhosis Treatment by Drug Repositioning and Leaky Gut Control
2021 - 2023 Development research of novel pathophysiology and therapy for hepatorenal syndrome in cirrhosis-Thrombotic microangiopathy and recombinant ADAMTS13 therapy-
2017 - 2020 Therapeutic effect of Equol on gut microbiome - mediated NASH progression
2014 - 2017 Establishment of new treatment targeting lifestyle diseases and coagulation fibrinolytic system related to the development of NASH
2015 - 2017 Identification of novel treatment and biomarkers based on pharmacokinetics in patients with hepatocellular carcinoma
2014 - 奈良県立医科大学 公立大学法人若手研究助成事業
2011 - 2013 Gut-liver axis mediated by endotoxin and innate immunity
Show all
Papers (277)：
Fumimasa Tomooka, Koh Kitagawa, Akira Mitoro, Yukihisa Fujinaga, Norihisa Nishimura, Tadashi Namisaki, Takemi Akahane, Kosuke Kaji, Shohei Asada, Shinya Sato, et al. Unilateral drainage and chemotherapy prolong the patency of a plastic stent placed above the sphincter of Oddi in patients with malignant hilar biliary obstruction. DEN open. 2025. 5. 1. e404
Jun-Ichi Hanatani, Koh Kitagawa, Fumimasa Tomooka, Shohei Asada, Akira Mitoro, Yukihisa Fujinaga, Norihisa Nishimura, Shinya Sato, Akihiko Shibamoto, Yuki Fujimoto, et al. Impact of the COVID-19 pandemic on the treatment of acute cholangitis caused by choledocholithiasis: A single-center retrospective study in Japan. DEN open. 2025. 5. 1. e371
Takuya Matsuda, Kosuke Kaji, Norihisa Nishimura, Shohei Asada, Aritoshi Koizumi, Misako Tanaka, Nobuyuki Yorioka, Yuki Tsuji, Koh Kitagawa, Shinya Sato, et al. Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity. Heliyon. 2024. 10. 19. e38647
Aritoshi Koizumi, Kosuke Kaji, Norihisa Nishimura, Shohei Asada, Takuya Matsuda, Misako Tanaka, Nobuyuki Yorioka, Yuki Tsuji, Koh Kitagawa, Shinya Sato, et al. Effects of elafibranor on liver fibrosis and gut barrier function in a mouse model of alcohol-associated liver disease. World journal of gastroenterology. 2024. 30. 28. 3428-3446
Satoshi Iwai, Takemi Akahane, Hiroaki Takaya, Takahiro Kubo, Fumimasa Tomooka, Akihiko Shibamoto, Junya Suzuki, Yuki Tsuji, Yukihisa Fujinaga, Norihisa Nishimura, et al. Ratio of von Willebrand factor to ADAMTS13 is a useful predictor of esophagogastric varices progression after sustained virologic response in patients with hepatitis C virus-related liver cirrhosis. Hepatology research : the official journal of the Japan Society of Hepatology. 2024
2002 - 2006 Nara Medical University Graduate School of Medical Science Course
1997 - 2002 Nara Medical University
1991 - 1997 Osaka Medical College
Work history (7)：
2019/10 - 現在 奈良県立医科大学 消化器代内科 講師
2016/04 - 2019/09 Nara Medical University
2015/10 - 2016/03 奈良県立医大 内科学第三講座 学内講師
2013/04 - 2015/09 Nara Medical University
2012/01 - 2013/03 Nara Medical University
2009/10 - 2011/12 Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology
2006/04 - 2009/09 奈良県立医科大学消化器内分泌代謝内科 博士研究員
Show all
Committee career (5)：
2018/12 - 現在 日本消化器病学会評議員
2017/04 - 現在 日本内科学会 近畿支部評議員
2015/12 - 現在 日本肝臓学西部会評議員
2014/01 - 現在 日本消化器病学会支部評議員
2020/04 - 2022/03 日本肝臓学会 学会評議員
Awards (4)：
2009 - Asian Pacific Association for the Study of the Liver (APASL) Conference Presidential Poster of Distinction
2007 - Nara Medical Association Academic Award
2005/11 - Annual Meeting of American Association for the Study liver Diseases Presidential Poster of Distinction
2005/10 - 日本肝臓学会 ポスターセッション優秀演題賞
Association Membership(s) (4)：
THE JAPANESE SOCIETY OF INTERNAL MEDICINE
, JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY
, JAPANESE SOCIETY OF GASTROENTEROLOGY
, THE JAPAN SOCIETY OF HEPATOLOGY
